Plasma and urinary cyclic nucleotide levels in patients with lung cancer

In order to evaluate a clinical significance of cyclic adenosine 3', 5'-monophosphate (cAMP) and cyclic guanosine 3', 5'-monophosphate (cGMP) as a marker, plasma and 24-hour urinary levels were measured in 84 patients with lung cancer, 25 normal subjects, 21 patients with benign...

Full description

Saved in:
Bibliographic Details
Published inJapanese Journal of National Medical Services Vol. 43; no. 7; pp. 736 - 740
Main Authors FUJII Masafumi, KIURA Katsuyuki
Format Journal Article
LanguageJapanese
Published Japanese Society of National Medical Services 1989
一般社団法人 国立医療学会
Subjects
Online AccessGet full text
ISSN0021-1699
1884-8729
DOI10.11261/iryo1946.43.736

Cover

More Information
Summary:In order to evaluate a clinical significance of cyclic adenosine 3', 5'-monophosphate (cAMP) and cyclic guanosine 3', 5'-monophosphate (cGMP) as a marker, plasma and 24-hour urinary levels were measured in 84 patients with lung cancer, 25 normal subjects, 21 patients with benign lung disease, and 7 patients with benign lung tumor. Plasma cAMP levels in patients with lung cancer were significantly lower than those of normal subjects and patients with benign lung disease, while plasma cGMP levels in patients with lung cancer were significantly higher than those of normal subjects and patients with benign lung disease. Urinary cAMP levels in patients with lung cancer were similar to those of normal subjects, patients with benign lung disease and patients with benign lung tumor, whereas urinary cGMP levels were significantly higher than those of these three groups. Plasma cGMP levels were strongly correlated with urinary cGMP levels in patients with lung cancer. Plasma and urinary cGMP levels increased with the progression of clinical stages in patients with lung cancer. These results suggest that plasma and urinary cGMP levels are useful markers in patients with lung cancer. 原発性肺癌84例, 健常人25例, 良性肺疾患21例, 良性肺腫瘍7例において血漿中および尿中のcyclic nucleotide値を測定し, その臨床的意義について検討した. 血漿中cAMP値は原発性肺癌で健常人, 良性肺疾患より有意に低値であり, 血漿中cGMP値は原発性肺癌で健常人, 良性肺疾患より有意に高値であつた. 尿中cAMP値は4群間で差を認めなかつたが, 尿中cGMP値は原発性肺癌で健常人, 良性肺疾患, 良性肺腫瘍より有意に高値を示した. 原発性肺癌においては血漿中cGMP値と尿中cGMP値との間に有意な正相関を認めた. 原発性肺癌の臨床病期別の検討では血漿中cGMP値は病期の進行とともに上昇し, III, IV期ではI期に比べ有意に高値であつた. 尿中cGMP値も病期の進行にしたがつて増加し, IV期ではI期より有意に高値を示した. 以上より, 血漿中および尿中のcGMPは原発性肺癌の臨床診断, 病勢把握に対して有用なマーカーになり得ると考えられた.
ISSN:0021-1699
1884-8729
DOI:10.11261/iryo1946.43.736